Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Realm Therapeutics PLC    PURI   GB00B3XBCR18

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsRevisions 
News SummaryMost relevantAll newsSector newsTweets 

PuriCore plc : PuriCore Raises $3.5 Million

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/03/2012 | 09:11pm CEST
PuriCore plc ("PuriCore" or the "Company" or the "Group") PuriCore Raises $3.5 Million MALVERN, PENNSYLVANIA, AND STAFFORD, UK, 3 January 2012 - PuriCore (LSE: PURI), the water- based clean technology company focused on developing and commercialising proprietary, green solutions that safely, effectively, and naturally kill infectious pathogens, announces that it closed on a new $3.5 million debt facility with Republic Bank on 29 December 2011. The debt will be utilized to finance the working capital requirements associated with Sterilox Fresh and FloraFresh System installations in H1 2012. The facility is structured as a promissory note with an imputed interest rate of 4%. Enquiries:

FTI Consulting Susan Quigley Ben Brewerton

+44 (0) 20 7831 3113

About PuriCore

PuriCoreplc (LSE: PURI) is a water-based clean technology company focused on developing and commercialising proprietary green solutions that safely, effectively, and naturally kill infectious pathogens without causing harm to human health or the environment. The Company's products are used in a broad range of markets that depend upon controlling contamination, including food retail and foodservice, medical device disinfection, and wound care. PuriCore's solutions are proven to be safe, environmentally friendly, and fast acting against a broad range of infectious pathogens, including major public health threats of C.difficile, E.coli, HIV, Human and Animal Influenza (including H1N1 and H5N1), Legionella, MRSA, M.tuberculosis, Norovirus, and Salmonella. PuriCore is headquartered in Malvern, Pennsylvania, with operations in Stafford and Clevedon, UK.
To receive additional information on PuriCore, please visit our website at www.puricore.com, which does not form part of this press release.

1

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on REALM THERAPEUTICS PLC
03/23 REALM THERAPEUTICS : 2016 Loss Widens As It Progresses Pipeline
02/28 REALM THERAPEUTICS : FDA permits PR022 to Proceed to Phase 2 Trial
02/28 REALM THERAPEUTICS : Phase II Trials Of PR022 Cleared By US FDA
2016 PURICORE : Change of name
2016 PURICORE : Lead Candidates See Progress As It Plans Name Change
2016 PURICORE : Offloads Supermarket Retail Arm, Interim Loss Widens
2016 PURICORE : Granted Two US Patents For Skin Disorder Therapy Production
2016 PURICORE : To Submit New Drug Application For PR022 To FDA In 2017
2016 PURICORE : To Stop Selling ProduceFresh Until Registered As Pesticide
2016 PURICORE : Strategic Review and Trading Update
More news
Sector news : Biotechnology & Medical Research - NEC
04/28 REGENERON PHARMACEUTICALS : Sanofi beats profit forecasts, upbeat on prospects f..
04/28DJSanofi 1st-Quarter Net Profit Rises on Sale of Animal-Health Unit
04/27 AMGEN : Cost controls help offset lower Amgen first-quarter drug sales
04/26 New GlaxoSmithKline CEO wants fewer, bigger new drug launches
04/18 Johnson & Johnson first quarter revenue misses estimates; new forecast includ..
More sector news : Biotechnology & Medical Research - NEC
Advertisement
Financials ( GBP)
Sales 2017 0,66 M
EBIT 2017 -13,3 M
Net income 2017 -13,1 M
Finance 2017 2,49 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 20,3x
EV / Sales 2018 2,64x
Capitalization 15,9 M
More Financials
Chart REALM THERAPEUTICS PLC
Duration : Period :
Realm Therapeutics PLC Technical Analysis Chart | PURI | GB00B3XBCR18 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Managers
NameTitle
John Alexander Martin Chief Executive Officer & Executive Director
Charles Alexander Evan Spicer Non-Executive Chairman
Marella Thorell COO, CFO, Secretary & Executive Director
Christian Peters Chief Medical Officer
Joseph William Birkett Senior Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
REALM THERAPEUTICS PLC5.83%21
INCYTE CORPORATION23.95%25 426
QUINTILES IMS HOLDINGS..10.82%19 884
LONZA GROUP AG6.92%11 836
SEATTLE GENETICS, INC.29.43%9 741
CELLTRION, INC.--.--%9 653
More Results